Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001358810 | SCV001554662 | uncertain significance | Hereditary spastic paraplegia 63; Pontocerebellar hypoplasia type 9 | 2022-03-03 | criteria provided, single submitter | clinical testing | This variant is present in population databases (rs770051774, gnomAD 0.006%). This sequence change replaces proline, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 102 of the AMPD2 protein (p.Pro102Leu). This variant has not been reported in the literature in individuals affected with AMPD2-related conditions. ClinVar contains an entry for this variant (Variation ID: 1050854). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C15"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002548529 | SCV003623817 | uncertain significance | Inborn genetic diseases | 2022-05-11 | criteria provided, single submitter | clinical testing | The c.305C>T (p.P102L) alteration is located in exon 2 (coding exon 2) of the AMPD2 gene. This alteration results from a C to T substitution at nucleotide position 305, causing the proline (P) at amino acid position 102 to be replaced by a leucine (L). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Genome- |
RCV003346510 | SCV004050209 | uncertain significance | Hereditary spastic paraplegia 63 | 2023-04-11 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV003346511 | SCV004050210 | uncertain significance | Pontocerebellar hypoplasia type 9 | 2023-04-11 | criteria provided, single submitter | clinical testing |